Augmedix, Inc. (NASDAQ:AUGX) Short Interest Update

Augmedix, Inc. (NASDAQ:AUGX - Get Free Report) was the target of a significant growth in short interest during the month of April. As of April 30th, there was short interest totalling 1,690,000 shares, a growth of 36.3% from the April 15th total of 1,240,000 shares. Currently, 3.8% of the company's shares are sold short. Based on an average trading volume of 368,700 shares, the short-interest ratio is currently 4.6 days.

Augmedix Stock Performance

NASDAQ AUGX traded down $0.27 during trading on Friday, hitting $2.23. 809,774 shares of the company's stock traded hands, compared to its average volume of 302,257. The company has a debt-to-equity ratio of 0.66, a quick ratio of 2.41 and a current ratio of 2.41. The stock has a market capitalization of $108.96 million, a price-to-earnings ratio of -4.94 and a beta of 0.03. Augmedix has a 12-month low of $2.22 and a 12-month high of $6.25. The business has a 50 day moving average of $3.47 and a 200-day moving average of $4.49.

Augmedix (NASDAQ:AUGX - Get Free Report) last issued its earnings results on Monday, March 18th. The company reported ($0.09) earnings per share (EPS) for the quarter. The business had revenue of $12.68 million for the quarter, compared to the consensus estimate of $12.30 million. Augmedix had a negative net margin of 42.74% and a negative return on equity of 308.50%. As a group, equities research analysts anticipate that Augmedix will post -0.51 earnings per share for the current fiscal year.

Insider Activity at Augmedix

In other news, insider Ian Shakil sold 31,994 shares of the stock in a transaction on Thursday, March 28th. The shares were sold at an average price of $4.06, for a total transaction of $129,895.64. Following the completion of the sale, the insider now directly owns 187,666 shares in the company, valued at $761,923.96. The transaction was disclosed in a filing with the SEC, which is available at this link. Insiders have sold 251,323 shares of company stock worth $1,005,527 over the last ninety days. Insiders own 10.97% of the company's stock.

Institutional Trading of Augmedix

Institutional investors and hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. boosted its position in shares of Augmedix by 16.0% during the 1st quarter. Vanguard Group Inc. now owns 1,302,424 shares of the company's stock valued at $5,327,000 after acquiring an additional 179,534 shares during the last quarter. Blair William & Co. IL lifted its position in Augmedix by 30.6% during the first quarter. Blair William & Co. IL now owns 197,454 shares of the company's stock valued at $808,000 after purchasing an additional 46,265 shares during the last quarter. Oppenheimer Asset Management Inc. bought a new stake in Augmedix during the first quarter valued at approximately $56,000. SG Americas Securities LLC purchased a new position in Augmedix in the 1st quarter worth approximately $57,000. Finally, Essex Investment Management Co. LLC increased its holdings in shares of Augmedix by 31.1% in the 1st quarter. Essex Investment Management Co. LLC now owns 528,985 shares of the company's stock worth $2,164,000 after buying an additional 125,457 shares during the last quarter. 87.11% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on AUGX shares. Maxim Group lowered their target price on Augmedix from $6.50 to $5.00 and set a "buy" rating on the stock in a research report on Tuesday, March 19th. B. Riley started coverage on shares of Augmedix in a research report on Wednesday, April 3rd. They set a "buy" rating and a $5.50 target price for the company. Finally, Evercore ISI raised shares of Augmedix from an "in-line" rating to an "outperform" rating and raised their price target for the company from $4.50 to $5.00 in a research report on Tuesday, April 9th.

About Augmedix

Augmedix, Inc provides remote medical documentation solutions and live clinical support services in the United States. Its platform offers Augmedix Live that provides synchronous medical note documentation and point of care support; Augmedix Go Assist that offers asynchronous medical documentation based upon previously recorded visits; Augmedix Prep that provides patient demographics, past medical history, medication changes and other points from the patient's health record; and Augmedix Go, an autonomous, ambient AI mobile software application that offers fully automated medical documentation based upon recorded visits.